Antitumor Activity of a Binary EGFR/DNA Targeting Strategy Overcomes Resistance of Glioblastoma Stem cells to Temozolomide.

CONCLUSIONS: These findings provide the molecular basis of binary EGFR/DNA targeting and uncover the oral bioavailability, blood brain barrier permeability and antitumor activity of ZR2002 supporting potential evaluation of this first-in-class drug in recurrent GBM.
PMID: 31540977 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - September 19, 2019 Category: Cancer & Oncology Authors: Sharifi Z, Abdulkarim B, Meehan B, Rak J, Daniel P, Schmitt J, Lauzon N, Eppert K, Duncan HM, Petrecca K, Guiot MC, Jean-Claude BJ, Sabri S Tags: Clin Cancer Res Source Type: research